This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa (HS). HS is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The trial involves a treatment called Spesolimab, which is a solution for injection. Spesolimab is a type of medication known as a humanized monoclonal antibody, which is designed to target specific proteins in the body that may be involved in causing inflammation.

The purpose of this study is to assess the long-term safety of Spesolimab in people with HS who have already participated in a previous study with this medication. Participants in this trial will receive Spesolimab or a placebo, which is a substance with no active medication, to compare the effects. The study will monitor participants over a period to observe any side effects or changes in their condition.

Throughout the study, participants will receive regular injections of Spesolimab and will be closely monitored by healthcare professionals. The trial aims to provide valuable information on how safe and effective Spesolimab is for long-term use in treating HS. This information could help improve treatment options for people living with this challenging skin condition.